Last reviewed · How we verify
Experimental Arm: Ketamine
At a glance
| Generic name | Experimental Arm: Ketamine |
|---|---|
| Also known as | Ketalar |
| Sponsor | Assaf-Harofeh Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression (NA)
- Evaluation of Ketamine/Midazolam Sedation vs. Fentanyl/Midazolam Sedation for Image-Guided Percutaneous Procedures in Interventional Radiology (EARLY_PHASE1)
- Esketamine With or Without Integration Therapy for Treatment-Resistant Depression (PHASE4)
- Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression (PHASE2)
- A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis (PHASE3)
- Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department (PHASE3)
- Analgesic Effect of Bupivacaine Plus Ketamine Versus Bupivacaine Alone in Transversalis Fascia Plane Block (PHASE1)
- Ketamine & Crisis Response Plan for Suicidal Ideation in the ED (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |